Home / Technology & Devices

Technology & Devices

CENTOGENE Collaborates with PTC Therapeutics for Global Diagnostic Testing Program for AADC Deficiency

CAMBRIDGE, Ma. and ROSTOCK, Germany, Nov. 18, 2019 (GLOBE NEWSWIRE) — Centogene N.V. (NASDAQ: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, announced that it has signed an agreement with PTC Therapeutics, Inc. (PTC) …

Read More »

Finch Therapeutics and Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery Platform

SOMERVILLE, Mass.–(BUSINESS WIRE)–Finch Therapeutics Group, Inc. (“Finch”) and Takeda Pharmaceutical Company Limited (“Takeda”; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finch’s Human-First Discovery® platform. Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohn’s disease, a form of inflammatory …

Read More »

Centogene and Pfizer Enter New Data Access and Collaboration Agreement

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2019 (GLOBE NEWSWIRE) — CENTOGENE (Nasdaq: CNTG),  a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, announced today a new data access and collaboration agreement with Pfizer Inc. (NYSE: …

Read More »

Hologic Announces FDA Approval of 3DQuorum Imaging Technology, Powered by Genius AI

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved 3DQuorum™ Imaging Technology, powered by Genius AI™. 3DQuorum technology works in tandem with Hologic’s Clarity HD™ high resolution imaging technology to reduce tomosynthesis image volume for radiologists by 66 percent.2 In 2009, …

Read More »

FDA Grants De Novo Designation for Vela Diagnostics’ Next Generation Sequencing HIV-1 Genotyping Assay

FAIRFIELD, N.J.–(BUSINESS WIRE)–Vela Diagnostics announced today that it has received FDA authorization to market its in vitro diagnostic test for the detection of HIV-1 genomic drug resistance mutations (DRMs). The Sentosa® SQ HIV-1 Genotyping Assay uses the plasma of patients infected with HIV-1 to detect HIV-1 Group M DRMs in the protease, reverse transcriptase, …

Read More »

QIAGEN Expands Portfolio of Immuno-Oncology Assets for Future Companion Diagnostics and Biomarkers

Hilden, Germany, and Germantown, Maryland, November 5, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of agreements that expand its immuno-oncology assets for future commercialization of novel companion diagnostics for precision medicine in immuno-oncology, in particular based on the powerful next-generation sequencing (NGS) technology. The agreements …

Read More »

Siemens Healthineers Partners with Quanterix for Access to Nf-L Antibodies for Development of Nf-L Assays

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix’ proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will …

Read More »

Stryker Announces Deal to Acquire Wright Medical for $4 Billion

Kalamazoo, Michigan, Nov. 04, 2019 (GLOBE NEWSWIRE) — Stryker (NYSE: SYK) announced today a definitive agreement to acquire all of the issued and outstanding ordinary shares of Wright Medical Group N.V. (NASDAQ: WMGI) for $30.75 per share, or a total equity value of approximately $4.0 billion and a total enterprise …

Read More »

FDA Approves Myriad’s myChoice CDx Test to Help Identify Women Eligible for Treatment with Zejula in Late-Line Ovarian Cancer

SALT LAKE CITY, Oct. 23, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that the U.S. Food and Drug Administration (FDA) approved myChoice® CDx for use as a companion diagnostic by healthcare professionals to identify women with advanced ovarian cancer who are candidates for …

Read More »

Philips and the US Department of Defense Develop Technology Using AI to Identify Infection Before Observable Symptoms

ANDOVER, Mass. & WASHINGTON–(BUSINESS WIRE)–Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, the Defense Threat Reduction Agency (DTRA), and Defense Innovation Unit (DIU) of the U.S. Department of Defense (DoD) today announced highlights from an 18-month project in predictive health monitoring aimed at developing an early warning …

Read More »